...
首页> 外文期刊>International Journal of Basic & Clinical Pharmacology >Effect of trimethoprim-sulfamethoxazole vs. norfloxacin on fecal E. coli resistance pattern and efficacy in patients receiving prophylaxis for spontaneous bacterial peritonitis
【24h】

Effect of trimethoprim-sulfamethoxazole vs. norfloxacin on fecal E. coli resistance pattern and efficacy in patients receiving prophylaxis for spontaneous bacterial peritonitis

机译:甲氧苄氨嘧啶-磺胺甲基异恶唑与诺氟沙星对自发性细菌性腹膜炎预防患者粪便大肠杆菌抵抗模式和功效的影响

获取原文
           

摘要

Background: Spontaneous Bacterial Peritonitis (SBP) is an infection of ascitic fluid. It is highly mortal and recurrent condition, so prophylaxis with Norfloxacin (NOR) or Trimethoprim-sulfamethoxazole (TMP-SMX) seems to play an important role in the prevention of further episodes of SBP. Aims of the study were to assess the effect of TMP-SMX/NOR on the sensitivity pattern of fecal E. coli after long term prophylaxis in Spontaneous Bacterial Peritonitis (SBP) and to compare the efficacy of TMP-SMX and NOR in prophylaxis of SBP. Methods: An interventional, prospective, open label, single center study conducted in Maulana Azad medical college, New Delhi, India. 52 patients of SBP or with high risk of SBP were screened and finally 39 patients were recruited. Stool sensitivity testing of fecal E. coli was done and they were divided into TMP-SMX group(n=18) and NOR group(n=21) according to sensitivity. After 45±3 days (7 weeks) their stool sample was re-examined for change sensitivity pattern of E. coli . Efficacy variables like any episode of SBP, fever (FEV) resolution of ascites (ASC), bacteremia (BACT), extraperitoneal infection (EPI), liver transplantation (LT) or death (D) were noted throughout the period of 24 weeks. Results: Resistance developed in 60% vs. 48% in TMP-SMX vs. NOR group(p=0.46) after 45 days of prophylaxis. By the end of 24 weeks, Incidence of SBP (29%vs. 25%, p0.99), episodes of FEV(P=0.60), EPI(p0.99), ASC(p0.99) and death (14% vs. 16%, p0.99) were almost similar in both the groups (TMP-SMX vs. NOR) respectively. Conclusions: Both TMP-SMX and NOR showed same degree of resistance and found equi-efficacious when administered as long-term prophylactic therapy in SBP. TMP-SMX can be a suitable as well as cost effective alternative to NOR for the prophylaxis of SBP.
机译:背景:自发性细菌性腹膜炎(SBP)是一种腹水感染。它是高度致死性和复发性疾病,因此诺氟沙星(NOR)或甲氧苄啶-磺胺甲基异恶唑(TMP-SMX)的预防似乎在预防SBP进一步发作中起重要作用。该研究的目的是评估长期预防自发性细菌性腹膜炎(SBP)后TMP-SMX / NOR对粪便大肠杆菌敏感性模式的影响,并比较TMP-SMX和NOR在预防SBP中的功效。方法:在印度新德里毛拉纳·阿扎德医学院进行的一项干预性,前瞻性,开放标签,单中心研究。筛选了52例SBP或SBP高危患者,最后招募了39例患者。进行粪便大肠杆菌的粪便敏感性测试,根据敏感性将其分为TMP-SMX组(n = 18)和NOR组(n = 21)。在45±3天(7周)后,对他们的粪便样本进行重新检查,以了解大肠杆菌的变化敏感性模式。在整个24周的期间内,记录了SBP的任何发作,腹水的发热(FEV)消退(ASC),菌血症(BACT),腹膜外感染(EPI),肝移植(LT)或死亡(D)等功效变量。结果:预防45天后,抗药性分别为60%和48%(TMP-SMX与NOR组相比,p = 0.46)。到24周结束时,SBP发生率(29%vs。25%,p> 0.99),FEV发作(P = 0.60),EPI(p> 0.99),ASC(p> 0.99)和死亡(14% vs. 16%,p> 0.99)在两组中几乎都相似(TMP-SMX与NOR)。结论:TMP-SMX和NOR在SBP长期预防性治疗中均显示出相同程度的耐药性,并具有同等效力。 TMP-SMX可以作为NOR预防SBP的合适且具成本效益的替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号